Dr. Jay C. Andersen, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 411
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OR license MD25119
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
- Providence St Vincent Medical Center Portland, OR
- Providence Portland Medical Center Portland, OR
- Legacy Good Samaritan Medical Center Portland, OR
- Legacy Meridian PArk Medical Center Tualatin, OR
Medical groups
- Northwest Cancer Specialists PC (69 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 411
- Services billed
- 102,012
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 17,100 | 25 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12,750 | 20 |
| Injection, pembrolizumab, 1 mg | 7,000 | 17 |
| Injection, fosaprepitant, 1 mg | 4,800 | 24 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,255 | 22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 594 | 34 |
| Injection, palonosetron hcl, 25 mcg | 410 | 28 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 397 | 127 |
| Injection, granisetron hydrochloride, 100 mcg | 380 | 25 |
| Insertion of needle into vein for collection of blood sample | 356 | 119 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Portland, OR | 267 |
| Anastrozole Other prescribers in Portland, OR | 182 |
| Tamoxifen Citrate Other prescribers in Portland, OR | 116 |
| Folic Acid Other prescribers in Portland, OR | 54 |
| Eliquis (apixaban) Other prescribers in Portland, OR | 45 |
| Gabapentin Other prescribers in Portland, OR | 41 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Portland, OR | 40 |
| Ondansetron Hcl Other prescribers in Portland, OR | 34 |
| Prochlorperazine Maleate Other prescribers in Portland, OR | 29 |
| Ibrance (palbociclib) | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $78.10 in total to this clinician.
| Astellas Pharma US Inc | $37.61 |
|---|---|
| Novartis Pharmaceuticals Corporation | $20.49 |
| Aveo Pharmaceuticals, Inc. | $20.00 |
| Food and Beverage | $58.10 |
|---|---|
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Jan 13, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $1,839,898 in research payments for these studies, mostly to the institutions running them.
- A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Novartis Pharmaceuticals Corporation - A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
AstraZeneca Pharmaceuticals LP - Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca Pharmaceuticals LP - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Janssen Research & Development, LLC - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997 - A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Posi…
Merck Sharp & Dohme LLC - A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast C…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.